Literature DB >> 27354024

Non-Hodgkin lymphoma in the developing world: review of 4539 cases from the International Non-Hodgkin Lymphoma Classification Project.

Anamarija M Perry1, Jacques Diebold2, Bharat N Nathwani3, Kenneth A MacLennan4, Hans K Müller-Hermelink5, Martin Bast6, Eugene Boilesen7, James O Armitage1, Dennis D Weisenburger8.   

Abstract

The distribution of non-Hodgkin lymphoma subtypes varies around the world, but a large systematic comparative study has never been done. In this study, we evaluated the clinical features and relative frequencies of non-Hodgkin lymphoma subtypes in five developing regions of the world and compared the findings to the developed world. Five expert hematopathologists classified 4848 consecutive cases of lymphoma from 26 centers in 24 countries using the World Health Organization classification, and 4539 (93.6%) were confirmed to be non-Hodgkin lymphoma, with a significantly greater number of males than females in the developing regions compared to the developed world (P<0.05). The median age at diagnosis was significantly lower for both low- and high-grade B-cell lymphoma in the developing regions. The developing regions had a significantly lower frequency of B-cell lymphoma (86.6%) and a higher frequency of T- and natural killer-cell lymphoma (13.4%) compared to the developed world (90.7% and 9.3%, respectively). Also, the developing regions had significantly more cases of high-grade B-cell lymphoma (59.6%) and fewer cases of low-grade B-cell lymphoma (22.7%) compared to the developed world (39.2% and 32.7%, respectively). Among the B-cell lymphomas, diffuse large B-cell lymphoma was the most common subtype (42.5%) in the developing regions. Burkitt lymphoma (2.2%), precursor B- and T-lymphoblastic leukemia/lymphoma (1.1% and 2.9%, respectively) and extranodal natural killer/T-cell lymphoma (2.2%) were also significantly increased in the developing regions. These findings suggest that differences in etiologic and host risk factors are likely responsible, and more detailed epidemiological studies are needed to better understand these differences. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2016        PMID: 27354024      PMCID: PMC5046654          DOI: 10.3324/haematol.2016.148809

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  39 in total

1.  Follicular lymphoma in Osaka, Japan: histological features and chronological change.

Authors:  Hajime Miyazato; Shin-ichi Nakatsuka; Itsuko Miyanaga; Hitoshi Hanamoto; Yoichi Tatsumi; Mitsuhiro Matsuda; Yasuhiro Maeda; Akihisa Kanamaru; Katsuyuki Aozasa
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

2.  The challenge of lymphomas in sub-Saharan Africa.

Authors:  Francesca Cainelli; Matthew N Tanko; Sandro Vento
Journal:  Lancet Oncol       Date:  2010-07       Impact factor: 41.316

3.  Relative frequency of non-Hodgkin lymphoma subtypes in selected centres in North Africa, the middle east and India: a review of 971 cases.

Authors:  Anamarija M Perry; Jacques Diebold; Bharat N Nathwani; Kenneth A MacLennan; Hans K Müller-Hermelink; Martin Bast; Eugene Boilesen; James O Armitage; Dennis D Weisenburger
Journal:  Br J Haematol       Date:  2015-12-18       Impact factor: 6.998

4.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001.

Authors:  Lindsay M Morton; Sophia S Wang; Susan S Devesa; Patricia Hartge; Dennis D Weisenburger; Martha S Linet
Journal:  Blood       Date:  2005-09-08       Impact factor: 22.113

5.  Viral and non-viral risk factors for non-Hodgkin's lymphoma in Egypt: heterogeneity by histological and immunological subtypes.

Authors:  Lenka Goldman; Sameera Ezzat; Nadia Mokhtar; Amany Abdel-Hamid; Nathan Fowler; Iman Gouda; Soheir Abdel Latif Eissa; Mohamed Abdel-Hamid; Christopher A Loffredo
Journal:  Cancer Causes Control       Date:  2009-03-05       Impact factor: 2.506

Review 6.  Gender perspectives and quality of care: towards appropriate and adequate health care for women.

Authors:  C M Gijsbers van Wijk; K P van Vliet; A M Kolk
Journal:  Soc Sci Med       Date:  1996-09       Impact factor: 4.634

7.  Non-Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011.

Authors:  Mohammed Al-Hamadani; Thomas M Habermann; James R Cerhan; William R Macon; Matthew J Maurer; Ronald S Go
Journal:  Am J Hematol       Date:  2015-07-27       Impact factor: 10.047

8.  Medical history, lifestyle, family history, and occupational risk factors for mantle cell lymphoma: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Authors:  Karin E Smedby; Joshua N Sampson; Jennifer J Turner; Susan L Slager; Marc Maynadié; Eve Roman; Thomas M Habermann; Christopher R Flowers; Sonja I Berndt; Paige M Bracci; Henrik Hjalgrim; Dennis D Weisenburger; Lindsay M Morton
Journal:  J Natl Cancer Inst Monogr       Date:  2014-08

9.  The investigation of Epstein-Barr viral sequences in 41 cases of Burkitt's lymphoma from Egypt: epidemiologic correlations.

Authors:  N Anwar; D W Kingma; A R Bloch; M Mourad; M Raffeld; J Franklin; I Magrath; N el Bolkainy; E S Jaffe
Journal:  Cancer       Date:  1995-10-01       Impact factor: 6.860

10.  Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6-19, 2003-2010.

Authors:  Jennifer Beam Dowd; Tia Palermo; Jennifer Brite; Thomas W McDade; Allison Aiello
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more
  41 in total

1.  Quantitative Assessment of Interim PET/CT Could Have More Prognostic Relevance than Visual Assessment for Predicting Clinical Outcome of Extranodal Diffuse Large B Cell Lymphoma.

Authors:  Dong Won Baek; Hee Jeong Cho; Ju-Hyung Kim; Sang Kyun Sohn; Ga-Young Song; Seo-Yeon Ahn; Sung-Hoon Jung; Jae Sook Ahn; Je-Jung Lee; Hyeoung-Joon Kim; Shin-Young Jeong; Chae Moon Hong; Jung-Joon Min; Joon-Ho Moon; Deok-Hwan Yang
Journal:  In Vivo       Date:  2020 Jul-Aug       Impact factor: 2.155

2.  Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities.

Authors:  Elizabeth A Morgan; M Patrick Sweeney; Tamiwe Tomoka; Nadja Kopp; Daniel Gusenleitner; Robert A Redd; Christopher D Carey; Leo Masamba; Steve Kamiza; Geraldine S Pinkus; Donna S Neuberg; Scott J Rodig; Danny A Milner; David M Weinstock
Journal:  Blood Adv       Date:  2016-11-22

Review 3.  Epidemiology of Follicular Lymphoma.

Authors:  James R Cerhan
Journal:  Hematol Oncol Clin North Am       Date:  2020-05-05       Impact factor: 3.722

4.  Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma.

Authors:  Hu Zhao; Yuan Chen; You-Ping Liao; Hai-Mei Chen; Qiu-Hong Yang; Yin Xiao; Jing Luo; Zhen-Zhen Chen; Lai Yi; Guo-Yu Hu
Journal:  Clin Exp Med       Date:  2022-03-03       Impact factor: 3.984

5.  The prognostic value of end-of-treatment FDG-PET/CT in diffuse large B cell lymphoma: comparison of visual Deauville criteria and a lesion-to-liver SUVmax ratio-based evaluation system.

Authors:  Ying-He Li; Yu-Mo Zhao; Yong-Luo Jiang; Si Tang; Mei-Ting Chen; Zi-Zheng Xiao; Wei Fan; Ying-Ying Hu; Xu Zhang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-10-15       Impact factor: 9.236

6.  The clinical characteristics and prognostic factors of 410 patients with natural killer/T-cell lymphoma.

Authors:  Zhenchang Sun; Wenjuan Wan; Xudong Zhang; Lei Zhang; Xin Li; Ling Li; Xinhua Wang; Feifei Nan; Hui Yu; Yu Chang; Jiaqin Yan; Zhaoming Li; Fangfang Cui; Jurui Ge; Yaqin Duo XiaXu; Xia Xu; Xiaorui Fu; Mingzhi Zhang
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-20       Impact factor: 4.322

7.  Dimerization of an aptamer generated from Ligand-guided selection (LIGS) yields a high affinity scaffold against B-cells.

Authors:  Sana Batool; Kimon V Argyropoulos; Roksana Azad; Precious Okeoma; Hasan Zumrut; Sanam Bhandari; Rigzin Dekhang; Prabodhika R Mallikaratchy
Journal:  Biochim Biophys Acta Gen Subj       Date:  2018-10-17       Impact factor: 3.770

8.  Avadomide monotherapy in relapsed/refractory DLBCL: safety, efficacy, and a predictive gene classifier.

Authors:  Cecilia Carpio; Reda Bouabdallah; Loïc Ysebaert; Juan-Manuel Sancho; Gilles Salles; Raul Cordoba; Antonio Pinto; Mecide Gharibo; Drew Rasco; Carlos Panizo; Jose A Lopez-Martin; Armando Santoro; Antonio Salar; Silvia Damian; Alejandro Martin; Gregor Verhoef; Eric Van den Neste; Maria Wang; Suzana Couto; Soraya Carrancio; Andrew Weng; Xuehai Wang; Frank Schmitz; Xin Wei; Kristen Hege; Matthew W B Trotter; Alberto Risueño; Tonia J Buchholz; Patrick R Hagner; Anita K Gandhi; Michael Pourdehnad; Vincent Ribrag
Journal:  Blood       Date:  2020-03-26       Impact factor: 22.113

9.  Epidemiology of Marginal Zone Lymphoma.

Authors:  James R Cerhan; Thomas M Habermann
Journal:  Ann Lymphoma       Date:  2021-03-30

10.  Chronic viral hepatitis, HIV infection and Non-Hodgkin lymphomas in West Africa, a case-control study.

Authors:  Antoine Jaquet; Simon P Boni; Kouakou Boidy; Judicaël Tine; Boris Tchounga; Sokhna A Touré; Jean-Jacques Koffi; Cherif Dial; Alain Monnereau; Isidore Diomande; Aristophane Tanon; Moussa Seydi; François Dabis; Saliou Diop; Gustave Koffi
Journal:  Int J Cancer       Date:  2021-06-19       Impact factor: 7.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.